VJOncology Podcast
VJOncology Podcast
VJOncology
Lung cancer at ESMO 2025: new targets, biomarkers & the changing landscape
14 minutes Posted Nov 26, 2025 at 10:11 am.
Introduction to Lung Cancer Findings
Small Cell Lung Cancer Insights
HER2 Mutant Non-Small Cell Lung Cancer
Exploring Biomarkers in Lung Cancer
Themes from ESMO 2025 and Beyond
0:00
14:13
Download MP3
Show notes

In this episode of the VJOncology Podcast, we bring you four standout interviews from ESMO 2025 that are reshaping the way we think about lung cancer. From antibody-drug conjugates and bispecific T-cell engagers through novel HER2-targeted TKIs to tumour-immune microenvironment biomarkers, the treatment paradigm is evolving rapidly.

Join us as we explore findings from the Phase III OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutant non-small-cell lung cancer (NSCLC) post-TKI progression, safety analysis of DeLLphi-304: tarlatamab vs standard chemo in small-cell lung cancer (SCLC), the first-line Beamion LUNG-1 experience of zongertinib in advanced HER2-mutant NSCLC and biomarker insights from the ImmunoDriver-2 analysis.

We’ll weave together how these advances hint at a future where molecular and immunologic profiling come together: identifying patients who will benefit most, integrating new treatment classes, and navigating safety/survivorship in more complex regimens.